黄灿华教授 实验室


202. Gao Y, Tian H, Zhang T, Deng K, Liu S, Li J, Nice EC, Huang C, Ding H, Xuan R. Step-by-step Guided Photo-chemotherapy Nanoplatforms for Efficiently Suppressing Cervical Carcinoma Metastasis by Hijacking Intracellular Metabolism. Chem Eng J. In press.


201. Deng K, Tian H, Zhang T, Gao Y, Nice EC, Huang C, Xie N, Ye G, Zhou Y. Chemo-photothermal nanoplatform with diselenide as the key for ferroptosis in colorectal cancer. J Control Release. 2024; 366:684-693.


200. Liu S, Tian H, Ming H, Zhang T, Gao Y, Liu R, Chen L, Yang C, Nice EC, Huang C, Bao J, Gao W, Shi Z. Mitochondrial-Targeted CS@KET/P780 Nanoplatform for Site-Specific Delivery and High-Efficiency Cancer Immunotherapy in Hepatocellular Carcinoma. Adv Sci (Weinh). 2024:e2308027.


199. Ding K, Tian H, Li L, Liu S, Ding N, Nice EC, Bao J, Gao W, Shi Z. Drug Repurposing-based Nanoplatform Via Modulating Autophagy to Enhance Chemo-phototherapy Against Colorectal Cancer. J Nanobiotechnol. 2024; 22(1):202.


198. He B, Huang Z, Qin S, Peng P, Duan X, Wang L, Ye Q, Wang K, Jiang J, Li B, Liu R, Huang C. Enhanced SLC35B2/SAV1 sulfation axis promotes tumor growth through inhibiting Hippo signaling in hepatocellular carcinoma. Hepatology. 2024; 10.1097/HEP.0000000000000783.


197. Huang Z, Zhou L, Duan J, Qin S, Jiang J, Chen H, Wang K, Liu R, Yuan M, Tang X, Nice EC, Wei Y, Zhang W*, Huang C*. Oxidative Stress Promotes Liver Cancer Metastasis via RNF25-Mediated E-Cadherin Protein Degradation. Adv Sci. 2024; 29:e2306929.


196. Zhang T, Tian H, Qin S, Gao Y, Zhang X, Nice EC, Du Z, Huang C. Nanoengineering Calcium Peroxide-based Site-specific Delivery Platform to Efficiently Activate the cGAS-STING Pathway for Cancer Immunotherapy by Amplified Endoplasmic Reticulum Stress. Adv Funct Mater. 2024; 2313384.


195.Lu S, Tian H, Li B, Li L, Jiang H, Gao Y, Zheng L, Huang C, Zhou Y, Du Z, Xu J. An Ellagic Acid Coordinated Copper-Based Nanoplatform for Efficiently Overcoming Cancer Chemoresistance by Cuproptosis and Synergistic Inhibition of Cancer Cell Stemness. Small. 2023; 3:e2309215.


194. Cao J, Zhang Z, Zhou L, Luo M, Li L, Li B, Nice EC, He W, Zheng S, Huang C. Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy. MedComm. 2023; 4(6):e427


193. Li B, Ming H, Qin S, Zhou L, Huang Z, Jin P, Peng L, Luo M, Zhang T, Wang K, Liu R, Liou YC, Nice EC, Jiang J, Huang C. HSPA8 activates Wnt/β-catenin signaling to facilitate BRAF V600E colorectal cancer progression by CMA-mediated CAV1 degradation. Adv Sci. 2023; 16:e2306535


192. Liu G, Li B, Qin S, Nice EC, Yang J, Yang L, Huang C. Redox signaling-mediated tumor extracellular matrix remodeling: pleiotropic regulatory mechanisms. Cell Oncol (Dordr). 2023. Online publish ahead of print.


191. Tan Y, Wang Z, Xu M, Li B, Huang Z, Qin S, Nice EC, Tang J, Huang C. Oral squamous cell carcinomas: state of the field and emerging directions. Int J Oral Sci. 2023; 15(1):44. (ESI高被引论文)


190. Wang K, Fu S, Dong L, Zhang D, Wang M, Wu X, Shen E, Luo L, Li C, Nice EC, Huang C, Zou B. Periplocin suppresses the growth of colorectal cancer cells by triggering LGALS3 (galectin 3)-mediated lysophagy. Autophagy. 2023; 1-19.


189. Jiang H, Tian H, Wang Z, Li B, Chen R, Luo K, Lu S, Nice EC, Zhang W, Huang C, Zhou Y, Zheng S, Gao F. Laser-activatable oxygen self-supplying nanoplatform for efficiently overcoming colorectal cancer resistance by enhanced ferroptosis and alleviated hypoxic microenvironment. Biomater Res. 2023; 27(1):92.


188. Tian H, Duan J, Qin S, Li B, Edouard C. Nice, Zhang W, Lang T, Zhang H, Huang C. Clinical Chemotherapeutic Agent Coordinated Copper-based Nanoadjuvants for Efficiently Sensitizing Cancer Chemo-immunotherapy by Cuproptosis-mediated Mitochondrial Metabolic Reprogramming. Adv Funct Mater. 2023, 2306584.


187. Liu R, Li Q, Qin S, Qiao L, Yang M, Liu S, Nice EC, Zhang W, Huang C, Zheng S, Gao W. Sertaconazole-repurposed nanoplatform enhances lung cancer therapy via CD44-targeted drug delivery. J Exp Clin Cancer Res. 2023; 42(1):188.


186. Liang J, Li L, Tian H, Wang Z, Liu G, Duan X, Guo M, Liu J, Zhang W, Nice EC, Huang C, He W, Zhang H, Li Q. Drug Repurposing-Based Brain-Targeting Self-Assembly Nanoplatform Using Enhanced Ferroptosis against Glioblastoma. Small. 2023:e2303073.


185. Huang Z, Tan Y, Zhang W, Tang X, Nice EC*, Huang C*. Hippo signaling in cancer: regulatory mechanisms and therapeutic strategies. Aust J Chem. 2023; 76(6-8),399-412.


184. Jia W, Huang Z, Zhou L, Liou YC, Di Virgilio F, Ulrich H, Illes P, Zhang W, Huang C, Tang Y. Purinergic signalling in cancer therapeutic resistance: From mechanisms to targeting strategies. Drug Resist Updat. 2023; 70:100988.


183. Duan X, Tian H, Zheng S, Zhu J, Li C, He B, Li L, Jiang H, Lu S, Feng Y,   T. Bentley G, Zhang W, Huang C, Gao W, Xie N , Xie K. Photothermal-starvation Therapy Nanomodulator Capable of Inhibiting Colorectal Cancer Recurrence and Metastasis by Energy Metabolism Reduction. Adv Healthc Mater. 2023; 12(26):e2300968.


182. Jin P, Li L, Nice EC, Huang C. Nanomedicine based modulation of redox status for cancer therapy. Aust J Chem. 2023; 76(6-8),337-350.


181. Jiang H, Zuo J, Li B, Chen R, Luo K, Xiang X, Lu S, Huang C, Liu L*, Tang J*, Gao F*. Drug-induced Oxidative Stress in Cancer Treatments: Angel or Devil? Redox Biol. 2023; 63:102754.(ESI高被引论文)


180. Li Q, Zhou L, Qin S, Huang Z, Li B,   Liu R, Yang M, Nice EC,   Zhu H*, Huang C*. Proteolysis-targeting chimeras in biotherapeutics: current trends and future applications. Eur J Med Chem. 2023; 115447.


179. Ding N, He K, Tian H, Li L, Li Q, Lu S, Ding K, Liu J, Nice EC, Zhang W, Huang C*, Tang Y*, Shen Z*. Carrier-free delivery of thymopentin-regulated injectable nanogels via an enhanced cancer immunity cycle against melanoma metastasis. Materials Today Bio. 2023; 20:100645.


178. Li L, Peng P, Ding N, Jia W, Huang C*, Tang Y*. Oxidative Stress, Inflammation, Gut Dysbiosis: What Can Polyphenols Do in Inflammatory Bowel Disease. Antioxidants (Basel). 2023; 12(4):967.


177. Zhang X, Wang L, Li B, Shi J, Xu J, Yuan M. Targeting Mitochondrial Dysfunction in Neurodegenerative Diseases: Expanding the Therapeutic Approaches by Plant-Derived Natural Products. Pharmaceuticals (Basel). 2023; 16(2):277.


176. Wang K, Luo L, Fu S, Wang M, Wang Z, Dong L, Wu X, Dai L, Peng Y, Shen G, Chen H, Nice EC, Wei X, Huang C. PHGDH Arginine Methylation by PRMT1 Promotes Serine Synthesis and Represents a Therapeutic Vulnerability in Hepatocellular Carcinoma. Nat Commun. 2023; 14(1):1011.



175. Qiao L, Qin S, Weng N, Li B, Luo M, Zhang Z, Zhou L, Wang D, Huang C. Discovery of Canine Drug Toceranib Phosphate as a Repurposed Agent Against Human Hepatocellular Carcinoma. Liver Int. 2023;43(4):928-944.


174. Li Q, Qin S, Tian H, Liu R, Qiao L, Liu S, Li B, Yang M, Shi J, Nice EC, Li J, Lang T, Huang C. Nano-Econazole Enhanced PD-L1 Checkpoint Blockade for Synergistic Anti-Tumor Immunotherapy Against Pancreatic Ductal Adenocarcinoma. Small. 2023;e2207201.


173. Ming H, Li B, Jiang J, Qin S, Nice EC, He W, Lang T, Huang C. Protein degradation: expanding the toolbox to restrain cancer drug resistance. J Hematol Oncol. 2023;16(1):6.


172. Jia W, Zhou L, Li L, Zhou P, Shen Z. Nano- Based Drug Delivery of Polyphenolic Compounds for Cancer Treatment: Progress, Opportunities, and Challenges. Pharmaceuticals (Basel). 2023;16(1):101.


171. Tian H, Cao J, Li B, Nice EC, Mao H, Zhang Y, Huang C*. Managing the immune microenvironment of osteosarcoma: the horizons for osteosarcoma treatment. Bone research. 2023;11(1):11. (ESI高被引论文


170. Li L, Tian H, Zhang Z, Ding N, He K, Lu S, Liu R, Wu P, Wang Y, He B, Luo M, Peng P, Yang M, Nice EC, Huang C, Xie N*, Wang D*, Gao W*. Carrier-Free Nanoplatform via Evoking Pyroptosis and Immune Response against Breast Cancer. ACS Appl Mater Interfaces. 2023;15(1):452-468.


169. Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L*. Neoantigens: promising targets for cancer therapy. Signal Transduct Target Ther. 2023;8(1):9.(ESI高被引论文)


168. Qin S, Zhang Z, Huang Z, Luo Y, Weng N, Li B, Tang Y, Zhou L, Jiang J, Lu Y, Shao J, Xie N, Nice EC, Chen Z, Zhang J, Huang C*. CCT251545 Enhances Drug Delivery and Potentiates Chemotherapy in Multidrug-Resistant Cancers by Rac1-Mediated Macropinocytosis. Drug Resistance Updates. 2023; 66:100906.


167. Wang S, Zhou L, Tian H, Li B, Su M, Li Q, Nice EC, Huang C, Shao J, He T. Site-specific nanomodulator capable of modulation apoptosis for enhanced colorectal cancer chemo-photothermal therapy. J Nanobiotechnology. 2023;21(1):24.


166. Jiang J, Chen H, Jin P, Zhou L, Peng L, Huang Z, Qin S, Li B, Ming H, Luo M, Xie N, Gao W, Nice EC, Yu Q, Wei Y, Huang C*. Targeting PSAT1 to mitigate metastasis in tumors with p53-72pro variant. Signal Transduct Target Ther. 2023;8(1):65.


165. Li L, Jin P, Guan Y, Luo M, Wang Y, He B, Li B, He K, Cao J, Huang C, Li J, Shen Z. Exploiting Polyphenol Mediated Redox Reorientation in Cancer Therapy. Pharmaceuticals (Basel). 2022 Dec 12;15(12):1540.


164. Shi J, Tian H, Peng L, Huang C, Nice EC, Zou B, Zhang H*. A nanoplatform reshaping intracellular osmolarity and redox homeostasis against colorectal cancer.J Control Release. 2022;352:766-775.


163. Jia W, Tian H, Jiang J, Zhou L, Li L, Luo M, Ding N, Nice EC, Huang C*, Zhang H*. Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma. Small. 2022;e2205354.


162. Jin P, Jiang J, Zhou L, Huang Z, Qin S, Chen HN, Peng L, Zhang Z, Li B, Luo M, Zhang T, Ming H, Ding N, Li L, Xie N, Gao W, Zhang W, Nice EC, Wei Y, Huang C*. Disrupting metformin adaptation of liver cancer cells by targeting the TOMM34/ATP5B axis. EMBO Mol Med. 2022:e16082.


161. Lu S, Tian H, Li L, Li B, Yang M, Zhou L, Jiang H, Li Q, Wang W, Nice EC, Xie N*, Huang C*, Liu L*. Nanoengineering A Zeolitic Imidazolate Framework-8 Capable of Manipulating Energy Metabolism Against Cancer Chemo-Phototherapy Resistance. Small. 2022:e2204926.


160. Zhou L, Jiang J, Huang Z, Jin P, Peng L, Luo M, Zhang Z, Chen Y, Xie N, Gao W, Nice EC, Li J*, Chen H*, Huang C*. Hypoxia-induced lncRNA STEAP3-AS1 activates Wnt/β-catenin signaling to promote colorectal cancer progression by preventing m6A-mediated degradation of STEAP3 mRNA. Mol Cancer. 2022;21(1):168.   


159. Duan J, Huang Z, Nice EC, Xie N*, Chen M*, Huang C*. Current advancements and future perspectives of long noncoding RNAs in lipid metabolism and signaling. J Adv Res. 2022:S2090-1232(22)00188-6.


158. Tian H, Zhang T, Qin S ,Huang Z, Zhou L, Shi J, Nice EC, Xie N, Huang C*, Shen Z* . Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies. J Hematol Oncol. 2022;15(1):132.(ESI高被引论文)


157. Jin P, Jiang J, Zhou L, Huang Z, Nice EC, Huang C*, Fu L*. Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management. J Hematol Oncol. 2022;15,97.ESI高被引论文


156. Tian H, Zhou L, Wang Y, Nice EC, Huang C*, Zhang H*. A targeted nanomodulator capable of manipulating tumor microenvironment against metastasis. J Control Release. 2022;348:590-600.


155. Qin S, Li B, Ming H, Nice EC, Zou B*, Huang C*. Harnessing redox signaling to overcome therapeutic-resistant cancer dormancy. Biochim Biophys Acta Rev Cancer. 2022;1877(4):188749.


154. Luo M, Zhou L, Huang Z, Li B, Nice EC, Xu J*, Huang C*. Antioxidant therapy in cancer: rationale and progress. Antioxidants. 2022;11(6):1128.


153. Huang Z, Zhang Z, Zhou C*, Liu L*, Huang C*. Epithelial-mesenchymal transition: The history, regulatory mechanism, and cancer therapeutic opportunities. MedComm. 2022;3(2):e144.


152. Ming H, Li B, Tian H, Zhou L, Jiang J, Zhang T, Qiao L, Wu P, Nice EC, Zhang W, He W*, Huang C*, Zhang H*. A minimalist and robust chemo-photothermal nanoplatform capable of augmenting autophagy-modulated immune response against breast cancer. Mater Today Bio. 2022;15:100289.


151. Shi J, Zhou L, Huang H, Peng L, Xie N, Nice EC, Fu L, Jiang C*, Huang C*. Repurposing oxiconazole against colorectal cancer via PRDX2-mediated autophagy arrest. Int J Biol Sci. 2022;18(9):3747-61.


150. Fan Q, Zuo J, Tian H, Huang C, Nice EC, Shi Z*, Kong Q*. Nanoengineering a metal-organic framework for osteosarcoma chemo-immunotherapy by modulating indoleamine-2,3-dioxygenase and myeloid-derived suppressor cells. J Exp Clin Canc Res. 2022;41(1):1-17.


149. He B, Huang Z, Huang C*, Nice EC*. Clinical applications of plasma proteomics and peptidomics: towards precision medicine. Proteomics Clin Appl. 2022;2100097.


148. Liu R, Peng L, Zhou L, Huang Z, Zhou C*, Huang C*. Oxidative stress in cancer immunotherapy: molecular mechanisms and potential applications. Antioxidants (Basel). 2022;11(5):853.


147. Wang Y, Huang Z, Li B, Liu L*, Huang C*. The emerging roles and therapeutic implications of epigenetic modifications in ovarian cancer. Front Endocrinol. 2022;766.


146. Peng L, Jiang J, Zhou L, Nice EC, Huang C*. A cellular thermal shift assay for detecting amino acid sites involved in drug target engagement. STAR Protoc. 2022;101423.


145. Zuo J, Zhang Z, Luo M, Zhou L, Nice EC, Zhang W, Wang C*, Huang C*. Redox signaling at the crossroads of human health and disease. MedComm. 2022;3(2):e127.


144. Zhou L, Zhang Z, Nice EC, Huang C*, Zhang W*, Tang Y*. Circadian rhythms and cancers: the intrinsic links and therapeutic potentials. J Hematol Oncol. 2022;15(1):21.


143. Zuo J, Zhang Z, Li M, Yang Y, Zheng B, Wang P*, Huang C*, Zhou S*. The crosstalk between reactive oxygen species and noncoding RNAs: from cancer code to drug role. Mol Cancer. 2022;21(1):30.


142. Weng N, Qin S, Liu J, Huang X, Jiang J, Zhou L, Zhang Z, Xie N, Wang K, Jin P, Luo M, Peng L, Nice EC, Goel A, Han S*,   Huang C*, Zhu Q*. Repurposing econazole as a pharmacological autophagy inhibitor to treat pancreatic ductal adenocarcinoma. Acta Pharm Sin B. 2022;12(7):3085-3102.


141. Luo M, Huang Z, Yang X, Chen Y, Jiang J, Zhang L, Zhou L, Qin S, Jin P, Fu S, Peng L, Li B, Fang Y, Pu W, Gong Y, Liu Y, Ren Z, Liu QL, Wang C, Xiao F, He D, Zhang H, Li C, Xu H, Dai L, Peng Y, Zhou ZG, Huang C*, Chen HN*. PHLDB2 mediates cetuximab resistance via interacting with EGFR in latent metastasis of colorectal cancer. Cell Mol Gastroenterol Hepatol. 2021;S2352-345X(21):00261-7.


140. Zhang Z, Qin S, Chen Y, Zhou L, Yang M, Tang Y, Zuo J, Zhang J, Mizokami A, Nice EC, Chen H*, Huang C*, Wei X*. Inhibition of NPC1L1 disrupts adaptive responses of drug-tolerant persister cells to chemotherapy. EMBO Mol Med. 2022;14(2):e14903. (ESI高被引论文)


139. Yang M, Zhang Z, Nice EC, Wang C*, Zhang W*, Huang C*. Psychological intervention to treat distress: An emerging frontier in cancer prevention and therapy. Biochim Biophys Acta Rev Cancer. 2021;1877(1):188665.(被WHO收录)


138. Peng L, Jiang J, Chen H, Zhou L, Huang Z, Qin S, Jin P, Luo M, Li B, Shi J, Xie N, Deng L, Liou Y, Nice EC, Huang C*, Wei Y. Redox-sensitive cyclophilin A elicits chemoresistance through realigning cellular oxidative status in colorectal cancer. Cell Rep. 2021;37(9):110069.


137. Wang Z, Guo K, Liu Y, Huang C*, Wu M*. Dynamic impact of virome on colitis and colorectal cancer: immunity, inflammation, prevention and treatment. Semin Cancer Biol. 2021;S1044-579X(21):00254-6.


136. Li B, Huang Y, Ming H, Nice EC, Xuan R*, Huang C*. Redox Control of the Dormant Cancer Cell Life Cycle. Cells. 2021;10(10):2707.


135. Zheng X, Liu R, Zhou C, Yu H, Luo W, Zhu J, Liu J, Zhang Z, Xie N, Peng X, Xu X, Cheng L, Yuan Q, Huang C*, Zhou X*. ANGPTL4-mediated promotion of glycolysis facilitates the colonization of Fusobacterium nucleatum in colorectal cancer. Cancer Res. 2021;81(24):6157-6170.


134. Jiang J, Li B, He W*, Huang C*. Dietary serine supplementation: Friend or foe? Curr Opin Pharmacol. 2021;61:12-20.


133. Peng L, Yin HY*, Huang C*. CNMa-CNMa receptor at microbiome-gut-brain axis: novel target to regulate feeding decision. Signal Transduct Target Ther. 2021;6(1):283.


132. Tian H, Zhao S, Nice EC, Huang C, He W*, Zou B*, Lin J*. A cascaded copper-based nanocatalyst by modulating glutathione and cyclooxygenase-2 for hepatocellular carcinoma therapy. J Colloid Interface Sci. 2021;607(2):1516-1526.


131. An Y, Jiang J, Zhou L, Shi J, Jin P, Li L, Peng L, He S, Zhang W, Huang C, Zou B*, Xie N*. Peroxiredoxin 1 is essential for natamycin-triggered apoptosis and protective autophagy in hepatocellular carcinoma. Cancer Lett. 2021;521:210-223.



130. Gao W, Huang Z, Duan J, Nice EC, Lin J*, Huang C*. Elesclomol induces copper-dependent ferroptosis in colorectal cancer cells via degradation of ATP7A. Mol Oncol. 2021;15(12):3527-44.


129. Luo M, Yang X, Chen HN, Nice EC*, Huang C*. Drug resistance in colorectal cancer: An epigenetic overview. Biochim Biophys Acta Rev Cancer. 2021;1876(2):188623.


128. Zhang Z, Shi J, Nice EC, Huang C*, Shi Z*. The Multifaceted Role of Flavonoids in Cancer Therapy: Leveraging Autophagy with a Double-Edged Sword. Antioxidants (Basel). 2021;10(7):1138.


127. Su M, Zhang Z, Zhou L, Han C, Huang C*, Nice EC*. Proteomics, Personalized Medicine and Cancer. Cancers (Basel). 2021;13(11):2512.


126. Zhang P, Zou B, Liou YC*, Huang C*. The pathogenesis and diagnosis of sepsis post burn injury. Burns Trauma. 2021;9:047.


125. Wang Z, Guo K, Gao P, Pu Q, Lin P, Qin S, Xie N, Hur J, Li C*, Huang C*, Wu M*. Microbial and genetic-based framework identifies drug targets in inflammatory bowel disease. Theranostics. 2021;11(15):7491-506.


124. Wang Z, Pu Q*, Huang C*, Wu M*. Crosstalk Between Lung and Extrapulmonary Organs in Infection and Inflammation. Adv Exp Med Biol. 2021;1303:333-50.


123. Huang Z, Xie N, Illes P, Di Virgilio F, Ulrich H, Semyanov A, Verkhratsky A, Sperlagh B, Yu S, Huang C*, Tang Y*. From purines to purinergic signalling: molecular functions and human diseases. Signal Transduct Target Ther. 2021; 6(1):162. (ESI 高被引论文)


122. Liu J, Huang Z, Chen HN, Qin S, Chen Y, Jiang J, Zhang Z, Luo M, Ye Q, Xie N, Zhou Z, Wei Y, Xie K*, Huang C*. ZNF37A promotes tumor metastasis through transcriptional control of THSD4/TGF-β axis in colorectal cancer. Oncogene. 2021; 40(19):3394-407.


121. Ming H, Li B, Zhou L, Goel A*, Huang C*. Long non-coding RNAs and cancer metastasis: Molecular basis and therapeutic implications. Biochim Biophys Acta Rev Cancer. 2021; 1875(2):188519.


120. Xie N, Zhang L, Gao W, Huang C, Huber PE, Zhou X, Li C*, Shen G*, Zou B*. NAD + metabolism: pathophysiologic mechanisms and therapeutic potential. Signal Transduct Target Ther. 2020; 5(1):227.ESI 高被引论文


119. Qin S, Jiang J, Lu Y, Nice EC, Huang C*, Zhang J*, He W*. Emerging role of tumor cell plasticity in modifying therapeutic response. Signal Transduct Target Ther. 2020; 5(1):228.


118. Zhou L, Zhang Z, Huang Z, Nice EC, Zou B*, Huang C*. Revisiting cancer hallmarks: insights from the interplay between oxidative stress and non-coding RNAs. Molecular Biomedicine. 2020. doi.org/10.1186/s43556-020-00004-1.


117. Peng L, Jiang J, Tang B, Nice EC, Zhang YY*, Xie N*. Managing therapeutic resistance in breast cancer: from the lncRNAs perspective. Theranostics. 2020; 10(23):10360-77.


116. Li B, Jiang J, Assaraf YG, Xiao H, Chen Z-S*, Huang C*. Surmounting Cancer Drug Resistance: New Insights from the perspective of N6-Methyladenosine RNA Modification. Drug Resist Updat. 2020; 53:100720.ESI 高被引论文


115. Jiang J, Peng L, Wang K*, Huang C*. Moonlighting Metabolic Enzymes in Cancer: New Perspectives on the Redox Code. Antioxid Redox Signal. 2020; 34(13):979-1003.


114. Zhang Z, Zhou L, Xie N, Nice EC, Zhang T*, Cui Y-P*, Huang C*. Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduct Target Ther. 2020; 5(1):113.ESI 高被引论文


113. Zhang P, Li T, Wu X, Nice EC, Huang C*, Zhang Y*. Oxidative stress and diabetes: antioxidative strategies. Front Med. 2020; 14(5):583-600. (ESI 高被引论文)


112. Huang Z, Zhou J-K, Peng Y, He W*, Huang C*. The role of long noncoding RNAs in hepatocellular carcinoma. Mol Cancer. 2020; 19(1):77. (ESI 高被引论文)


111. Huang Z, Zhou J-K, Wang K, Chen H-N, Qin S, Liu J, Luo M, Chen Y, Jiang J, Zhou L, Zhu L, He J, Li J, Pu W, Gong Y, Li J, Ye Q, Dong D, Hu H, Zhou Z, Dai L, Wei Y, Huang C*, Wei X*, Peng Y*. PDLIM1 inhibits tumor metastasis through activating Hippo signaling in hepatocellular carcinoma. Hepatology. 2020; 71(5):1643-59.


110. Zhang Z, Gao W, Zhou L, Chen Y, Qin S, Zhang L, Liu J, He Y, Lei Y, Chen H-N, Han J, Zhou Z-G, Nice EC, Li C, Huang C*, Wei X*. Repurposing Brigatinib for the Treatment of Colorectal Cancer Based on Inhibition of ER-phagy. Theranostics. 2019; 9(17):4878-92.


109. He Y, Mohamedali A, Huang C, Baker MS*, Nice EC*. Oncoproteomics: Current status and future opportunities. Clin Chim Acta. 2019; 495:611-24.


108. An Y, Zhou L, Huang Z, Nice EC, Zhang H*, Huang C*. Molecular insights into cancer drug resistance from a proteomics perspective. Expert Rev Proteomics. 2019; 16(5):413-29.


107. Jiang J, Zhang L, Chen H-N, Lei Y, Zhang T, Wang Y, Jin P, Lan J, Zhou L, Huang Z, Li B, Liu Y, Gao W, Xie K, Zhou L, Nice EC, Peng Y, Cao Y, Wei Y, Wang K*,Huang C*. Regorafenib induces lethal autophagy arrest by stabilizing PSAT1 in glioblastoma. Autophagy. 2020; 16(1):106-22.


106. Chen H-N, Chen Y, Zhou Z-G, Wei Y, Huang C*. A novel role for ketoconazole in hepatocellular carcinoma treatment: linking PTGS2 to mitophagy machinery. Autophagy. 2019; 15(4):733-4.


105. Zhou L, Gao W, Wang K, Huang Z, Zhang L, Zhang Z, Zhou J, Nice EC, Huang C*. Brefeldin A Inhibits Colorectal Cancer Growth by Triggering Bip/Akt-regulated Autophagy. FASEB J. 2019; 33(4):5520-34.


104. Wang K, Jiang J, Lei Y, Zhou S, Wei Y, Huang C*. Targeting Metabolic-redox Circuits for Cancer Therapy. Trends Biochem Sci. 2019; 44(5):401-14.ESI 高被引论文


103. Zhang Z, Zhang L, Zhou L, Lei Y, Zhang Y*, Huang C*. Redox signaling and unfolded protein response coordinate cell fate decisions under ER stress. Redox Biol. 2019; 25:101047.ESI 高被引论文


102. Chen Y, Chen H-N, Wang K, Zhang L, Huang Z, Liu JY, Zhang Z, Luo MC, Lei YL,Peng Y, Zhou Z-G, Wei YQ, Huang C*. Ketoconazole exacerbates mitophagy to induce apoptosis by downregulating cyclooxygenase-2 in hepatocellular carcinoma. J Hepatol. 2019; 70(1): 66-77.


101. Liu Y, Guo JZ, Liu Y, Wang K, Ding W, Wang H, Liu X, Zhou S, Lu XC, Yang HB, XuC, Gao W, Zhou L, Wang YP, Hu W, Wei Y, Huang C*, Lei QY*. Nuclear Lactate Dehydrogenase A Senses ROS to Produce α-Hydroxybutyrate for HPV-induced Cervical Tumor Growth. Nat Commun. 2018; 9(1):4429.


100. Peng L, Cantor DI, Huang C, Wang K, Baker MS*, Nice EC*. Tissue and plasma proteomics for early stage cancer detection. Mol Omics. 2018; 14(6):405-23.


99. Lan J, Huang Z, Han J, Shao J*, Huang C*. Redox regulation of microRNAs incancer. Cancer Lett. 2018; 418:250-9.


98. Jin P, Lan J, Wang K, Baker MS, Huang C*, Nice EC*. Pathology, proteomics and the pathway to personalised medicine. Expert Rev Proteomics.2018;15(3):231-43.


97. Wang K, Zhang T, Lei Y, Li X, Jiang J, LanJ, Liu Y, Chen H, Gao W, Xie N, Chen Q, Zhu X, Liu X, Xie K, Nice EC, Wu M*,Huang C*, Wei Y. Identification of Annexin A2 as a Specific Bleomycin Target to Induce Pulmonary Fibrosis by Impeding TFEB-mediated Autophagic Flux. Autophagy. 2018; 14(2):269-82.


96. Jiang J, Wang K, Chen Y, Chen H, Nice EC*, Huang C*. Redox regulation in tumor cell epithelial-mesenchymal transition: molecular basis and therapeutic strategy. Signal Transduct Target Ther. 2017; 2:17036.


95. Jin P, Wang K, Huang C*, Nice EC*. Mining the fecal proteome: from biomarkers to personalised medicine. Expert Rev Proteomics. 2017; 14(5):445-59.


94. Fu S, Liu X, Luo M, Xie K, Nice EC, Zhang H*, Huang C*. Proteogenomic studies on cancer drug resistance: towards biomarker discovery and target identification. Expert Rev Proteomics. 2017; 14(4): 351-62.


93. Zhou L, Wen J, Huang Z, Nice EC, Huang C, Zhang H*, Li Q*. Redox proteomics screening cellular factors associated with oxidative stress in hepatocarcinogenesis. Proteomics Clin Appl. 2017; 11(3-4).


92. Wang K, Gao W, Dou Q, Chen H, Li Q, Nice EC, Huang C*. Ivermectin Induces PAK1-mediated Cytostatic Autophagy in Breast Cancer. Autophagy. 2016; 12(12)2498-9.


91. Huang Z, Ma L, Huang C, Li Q*, Nice EC*. Proteomic profiling of human plasma for cancer biomarker discovery. Proteomics. 2017; 17(6).


90. Dou Q, Chen H, Wang K, Yuan K, Lei Y, Li K, Lan J, Chen Y, Huang Z, Xie N, Zhang L, Xiang R, Nice EC, Wei Y and Huang C*. Ivermectin induces cytostatic autophagy by blocking PAK1/Akt axis in breast cancer. Cancer Res. 2016; 76(15):4457-69.


89. Li X, He S, Li R, Zhou X, Zhang S, Yu M, YeY, Wang Y, Huang C*, Wu M*. Pseudomonas aeruginosa infection augments inflammation through miR-301b repression of c-Myb-ediated immune activation and infiltration. Nat Microbiol. 2016; 1(10):16132.


88. Xie N, Yuan K, Zhou L, Wang K, Chen H, Lei Y, Lan J, Pu Q, Gao W, Zhang L, ShenG, Li Q, Xiao H, Tang H, Xiang R, He M, Feng P, Nice EC, Wei Y, Zhang H*, YangJ* and Huang C*. PRKAA1/AMPK restricts HBV replication through promotion of autophagic degradation. Autophagy. 2016; 12(9):1507-20.


87. Zhang J, Feng H, Zhao J, Feldman ER, Chen S, Yuan W, Huang C, Akbari, TibbettsSA, Feng P*. IκB Kinase ε Is an NFATc1 Kinase that Inhibits T Cell Immune Response. Cell Rep. 2016; 16(2):405-18.


86. Chen H, Wang S, Zhang H, Nice EC, Huang C*. Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities. Expert Rev Anticancer Ther. 2016; 16(8):827-38.


85. Liu Y, Li Q, Zhou L, Xie N, Nice EC, Zhang H*, Huang C* and Lei Y*. Cancer drug resistance: redox resetting renders a way. Oncotarget. 2016; 7(27):42740-61.


84. Huang Z, Zhou L, Chen Z, Nice EC, Huang C*. Stress Management by Autophagy:Implications for Chemoresistance. Int J Cancer. 2016; 139(1):23-32.


83. Zhou L, Wang K, Li Q, Nice EC, Zhang H*, Huang C*. Clinical proteomics-driven precision medicine for targeted cancer therapy: current overview and future perspectives. Expert Rev Proteomics. 2016; 13(4):367-81.


82. Chen HN, Yuan K, Xie N, Wang K, Huang Z, Chen Y, Dou Q, Wu M, Nice EC, ZhouZG*, Huang C*. PDLIM1 stabilizes the E-cadherin/Beta catenin complex to prevent epithelial-mesenchymal transition and metastatic potential of colorectal cancer cells. Cancer Res. 2016; 76(5):1122-34.


81. Li X, He S, Zhou X, Ye Y, Tan S, Zhang S, Li R, Yu M, Jundt MC, Hidebrand A,Wang Y, Li G*, Huang C*, Wu M*. Lyn delivers bacteria to lysosomes for eradication through TLR2-initiated autophagy related phagocytosis. PLoS Pathog. 2016; 12(1):e1005363.


80. Yuan K, Lei Y, Chen H, Chen Y, Zhang T, Li K, Xie N, Wang K, Feng X, Pu Q, YangW, Wu M, Xiang R, Feitelson MA, Nice EC, Wei Y, Huang C*. HBV-induced ROS accumulation promotes hepatocarcinogenesis through Snail-mediated epigenetic silencing of SOCS3. Cell Death Differ. 2016; 616–27.


79. Zhou L, Li Q, Wang J, Huang C*, Nice EC. Oncoproteomics: Trials and Tribulations. Proteomics Clin Appl. 2016; 10(4):516-31.


78. Zhang L, Wang K, Lei Y, Li Q, Nice EC, Huang C*. Redox Signaling: Potential Arbitrator of Autophagy and Apoptosis in Therapeutic Response. Free Radical Bio Med. 2015; 89:452-65.


77. Jiang J, Wang K, Nice EC, Zhang T, Huang C*. High-throughput screening ofcellular redox sensors using modern redox proteomics approaches. Expert Rev Proteomics. 2015; 12(5):543-55.


76. Ren F,Wang K, Zhang T, Jiang J, Nice EC*,Huang C*. New insights into redox regulation of stem cell self-renewal and differentiation. Biochim Biophys Acta. 2015; 1850(8):1518-26.


75. Feng S, Zhou L, Huang C, Xie K*, Nice EC*. Interactomics: toward protein function and regulation. Expert Rev Proteomics. 2015; 12(1):37-60.


74. Li X, Ye Y,Zhou X, Huang C*, Wu M*. Atg7 Enhances Host Defense against Infection via Downregulation of Superoxide but Upregulation of Nitric Oxide. J Immunol. 2015; 194(3):1112-21.


73. Liu R, HuangS, Lei Y, Zhang T, Wang K, Liu B, Nice EC, Xiang R, Xie K, Li J*,Huang C*. FGF8 promotes colorectal cancer growth and metastasis by activating YAP1. Oncotarget. 2015; 6(2):935-52.


72. Yuan K, Liu Y, Zhang L, Lan J, Gao W, Dou Q, Nice EC*, Huang C*. Thiol-based redox proteomics in cancer research. Proteomics. 2015; 15(2-3):287-99.


71. Lei Y, WangK, Deng L, Chen Y, Nice EC, Huang C*. Redox Regulation of Inflammation:Old Elements, a New Story. Med Res Rev. 2015; 35(2):306-40.


70. Feng S, ZhouL, Nice EC*, Huang C*. Fibroblast growth factor receptors:multifactorial-contributorsto tumor initiation and progression. Histol Histopathol. 2015; 30(1):13-31.


69. Yang W, ZouL, Huang C, Lei Y*. Redox regulation of cancer metastasis:molecularsignaling and therapeutic opportunities. Drug Dev Res. 2014; 75(5):331-41.


68. Liu R, Li J, Zhang T, Zou L, Chen Y, Wang K, Lei Y, Yuan K, Li Y, Lan J, ChengL, Xie N, Xiang R, Nice EC, Huang C*, Wei Y. Itraconazole suppresses the growthof glioblastoma through induction of autophagy: Involvement of abnormal cholesterol trafficking. Autophagy. 2014; 10(7):1241-55.


67. Wang K, Huang C, Nice E*. Recent advances in proteomics: towards the human proteome. Biomed Chromatogr. 2014; 28(6):848-57.


66. Wang K, Huang C*, Nice EC*. Proteomics, genomics and transcriptomics: their emerging roles inthe discovery and validation of colorectal cancer biomarkers. Expert Rev Proteomics. 2014; 11(2):179-205.


65. Li X, Zhou X, Ye Y, Li Y, Li J, Privratsky B, Wu E, Gao H, Huang C*, Wu M.Lyn   regulatesinflammatory responses inKlebsiella pneumoniae infection via the p38/NF-κBpathway. Eur J Immunol. 2014; 44(3):763-73.


64. Xie N, Chen X, Zhang T, Liu B*, Huang C*. Using proteomics to identify the HBx interactome inhepatitis B virus: how can this inform the clinic? Expert Rev Proteomics. 2014; 11(1):59-74.


63. Liu R, Li J, Xie K, Zhang T, Lei Y, Chen Y, Zhang L, Huang K, Wang K, Wu H, WuM, Nice EC, Huang C*, Wei Y. FGFR4 promotes stroma-induced epithelial-to-mesenchymal transition incolorectal cancer. Cancer Res. 2013; 73(19):5926-35.


62. Wen X, Wu J,Wang F, Liu B*, Huang C*, Wei Y. Deconvoluting the role of reactiveoxygen speciesand autophagy in human diseases. Free Radic Biol Med. 2013; 65:402-10.


61. Liu R, Huang L, Li J, Zhou X, Zhang H, Zhang T, Lei Y, Wang K, Xie N, Zheng Y,Wang F, Nice EC,Rong L, Huang C*, Wei Y. HIV Infection in gastric epithelialcells. J Infect Dis. 2013; 208(8):1221-30.


60. Liu B, Wen X, Huang C*, Wei Y. Unraveling the complexity of hepatitis B virus: from molecular understanding to therapeutic strategy in 50 years. Int J Biochem Cell Biol. 2013 ;45(9):1987-96.


59. Wu J, Xie N, Xie K, Zeng J, Cheng L, Lei Y, Liu Y, Song L, Dong D, Chen Y, Zeng R, Nice EC, Huang C*, Wei Y. GPR48, a poor prognostic factor, promotes tumor metastasis and activates β-catenin/TCF signaling in colorectal cancer. Carcinogenesis. 2013 ;34(12):2861-9.

58. Yuan K, Xie K, Fox J, Zeng H, Gao H, Huang C*, Wu M*. Decreased levels of miR-224 and the passenger strand of miR-221 increase MBD2, suppressing maspin and promoting colorectal tumor growth and metastasis in mice. Gastroenterology. 2013; 145(4):853-64.e9.

57. Deng L, Lei Y, Liu R, Li J, Yuan K, Li Y, Chen Y, Liu Y, Lu Y, Edwards CK 3rd, Huang C*, Wei Y. Pyrvinium targets autophagy addiction to promote cancer cell death. Cell Death Dis. 2013; 4:e614.

56. Zhang T, Xie N, He W, Liu R, Lei Y, Chen Y, Tang H, Liu B*, Huang C, Wei Y. An integrated proteomics and bioinformatics analyses of hepatitis B virus X interacting proteins and identification of a novel interactor apoA-I. J Proteomics. 2013; 84:92-105.

55. Wang K, Zhang T, Dong Q, Nice EC, Huang C*, Wei Y. Redox homeostasis: the linchpin in stem cell self-renewal and differentiation. Cell Death Dis. 2013; 4:e537.

54. Zeng J, Yang X, Cheng L, Liu R, Lei Y, Dong D, Li F, Lau QC, Deng L, Nice EC, Xie K*, Huang C. Chemokine CXCL14 is associated with prognosis in patients with colorectal carcinoma after curative resection. J Transl Med. 2013; 11:6.

53. Zhou S, Liu R, Yuan K, Yi T, Zhao X*, Huang C*, Wei Y. Proteomics analysis of tumor microenvironment: Implications of metabolic and oxidative stresses in tumorigenesis. Mass Spectrom Rev. 2013; 32(4):267-311.

52. Klionsky DJ, Abdalla FC...Canhua H, et al., Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012; 8(4):445-44.


51. Wang K, Yang T, Wu Q, Zhao X, Nice EC, Huang C*. Chemistry-based functional proteomics for drug target deconvolution. Expert Rev Proteomics. 2012; 9(3):293-310.


50. Zhou S, Yi T, Liu R, Bian C, Qi X, He X, Wang K, Li J, Zhao X*, Huang C*, Wei Y. Proteomics identification of annexin A2 as a key mediator in the metastasis and proangiogenesis of endometrial cells in human adenomyosis. Mol Cell Proteomics. 2012; 11(7):M112.017988.   


49. Yuan K, Huang C*, Fox J, Laturnus D, Carlson E, Zhang B, Yin Q, Gao H, Wu M*. Autophagy plays an essential role in the clearance of Pseudomonas aeruginosa by alveolar macrophages. J Cell Sci. 2012; 125(Pt 2):507-15.


48. Zhou S, Li Y, Huang F, Zhang B, Yi T, Li Z, Luo H, He X, Zhong Q, Bian C, Lin X, Qi X, Liu P, Huang C, Zhao X*, Wei Y. Live-attenuated measles virus vaccine confers cell contact loss and apoptosis of ovarian cancer cells via ROS-induced silencing of E-cadherin by methylation. Cancer Lett. 2012; 318(1):14-25.


47. Lei Y, Xie K, Huang K, Wu H, Huang C*. Chemistry-based functional proteomics to identify novel deubiquitylating enzymes involved in viral infection. Comb Chem High Throughput Screen. 2012; 15(4):316-27.


46. Zhou M, Luo H, Li Z, Wu F, Huang C, Ding Z, Li R*. Recent advances in screening of natural products for antimicrobial agents. Comb Chem High Throughput Screen. 2012; 15(4):306-15.


45. Ou L, Duan D, Wu J, Nice E, Huang C*. The application of high throughput siRNA screening technology to study host-pathogen interactions. Comb Chem High Throughput Screen. 2012; 15(4):299-305.

44. Zeng J, Xie K, Wu H, Zhang B, Huang C*. Identification and functional study of cytokines and chemokines involved in tumorigenesis.
Comb Chem High Throughput Screen. 2012; 15(3):276-85.

43. Xie N, Huang K, Lei Y, Ran Y, Huang C*. Proteomics annotation of lipid rafts modified by virus infection.
Comb Chem High Throughput Screen. 2012; 15(3):253-65.

42. Liang S*, Xu Z, Xu X, Zhao X, Huang C, Wei Y. Quantitative proteomics for cancer biomarker discovery.
Comb Chem High Throughput Screen. 2012; 15(3):221-31.

41. Huang C*. Modern omics-based platform for high throughput screening for novel drug targets.
Comb Chem High Throughput Screen. 2012; 15(3):201.


40. Wu J, Xie N, Zhao X, Nice EC, Huang C*. Dissection of aberrant GPCR signaling in tumorigenesis--a systems biology approach. Cancer Genomics Proteomics. 2012; 9(1):37-50.

39. Xie N, Huang K, Zhang T, Lei Y, Liu R, Wang K, Zhou S, Li J, Wu J, Wu H, Deng C, Zhao X, Nice EC, Huang C*. Comprehensive proteomic analysis of host cell lipid rafts modified by HBV infection.
J Proteomics. 2012; 75(3):725-39.

38. Hu H, Deng C, Yang T, Dong Q, Chen Y, Nice EC, Huang C*, Wei Y. Proteomics revisits the cancer metabolome.
Expert Rev Proteomics. 2011; 8(4):505-33.

37. Zhou S, Liu R, Zhao X*, Huang C*, Wei Y. Viral proteomics: the emerging cutting-edge of virus research.
Sci China Life Sci. 2011; 54(6):502-12.


36. Lei Y, Huang K, Gao C, Lau QC, Pan H, Xie K, Li J, Liu R, Zhang T, Xie N, Nai HS, Wu H, Dong Q, Zhao X, Nice EC, Huang C*, Wei Y. Proteomics identification of ITGB3 as a key regulator in reactive oxygen species-induced migration and invasion of colorectal cancer cells. Mol Cell Proteomics. 2011; 10(10):M110.005397.

35. Wang K, Liu R, Li J, Mao J, Lei Y, Wu J, Zeng J, Zhang T, Wu H, Chen L, Huang C*, Wei Y. Quercetin induces protective autophagy in gastric cancer cells: involvement of Akt-mTOR- and hypoxia-induced factor 1α-mediated signaling.
Autophagy. 2011; 7(9):966-78.

34. Zeng D, Zhang T, Zhou S, Hu H, Li J, Huang K, Lei Y, Wang K, Zhao Y, Liu R, Li Q, Wen Y, Huang C. Proteomic analyses of gastric cancer cells treated with vesicular stomatitis virus matrix protein.
Protein J. 2011; 30(5):308-17.

33. Yuan K, Huang C*, Fox J, Gaid M, Weaver A, Li G, Singh BB, Gao H, Wu M. Elevated inflammatory response in caveolin-1-deficient mice with Pseudomonas aeruginosa infection is mediated by STAT3 protein and nuclear factor kappaB (NF-kappaB).
J Biol Chem. 2011; 286(24):21814-25.

32. Zhou S, Huang C*, Wei Y. The metabolic switch and its regulation in cancer cells.
Sci China Life Sci. 2010; 53(8):942-58.


31. Li J, Liu R, Lei Y, Wang K, Lau QC, Xie N, Zhou S, Nie C, Chen L, Wei Y, Huang C*. Proteomic analysis revealed association of aberrant ROS signaling with suberoylanilide hydroxamic acid-induced autophagy in Jurkat T-leukemia cells. Autophagy. 2010; 6(6):711-24.

30. Liu R, Wang K, Yuan K, Wei Y, Huang C*. Integrative oncoproteomics strategies for anticancer drug discovery. Expert Rev Proteomics. 2010; 7(3):411-29.

29. Ren F, Wu H, Lei Y, Zhang H, Liu R, Zhao Y, Chen X, Zeng D, Tong A, Chen L, Wei Y, Huang C*. Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma. Mol Cancer. 2010; 9:81.

28. Yuan K, Lei Y, Huang C*. Application of chemistry-based functional proteomics to screening for novel drug targets. Comb Chem High Throughput Screen. 2010; 13(5):414-21.

27. Li Z, Min W, Huang C, Bai S, Tang M, Zhao X*. Proteomics-based approach identified differentially expressed proteins with potential roles in endometrial carcinoma. Int J Gynecol Cancer. 2010; 20(1):9-15.

26. Kannan S, Huang H, Seeger D, Audet A, Chen Y, Huang C, Gao H, Li S, Wu M*. Alveolar epithelial type II cells activate alveolar macrophages and mitigate P. Aeruginosa infection. PLoS One. 2009; 4(3):e4891.

25. He J, Huang C, Tong A, Chen B, Zeng Z, Zhang P, Wang C*, Wei Y. Proteomic analysis of cervical cancer cells treated with suberonylanilide hydroxamic acid. J Biosci. 2008; 33(5):715-21.

24. Gou LT, Tong AP, Chen LJ, Tang MH, Chen B, Liang SF, Huang C*, Wei YQ*. Comparative plasma membrane-associated proteomics of immortalized human hepatocytes.   Biochemistry (Mosc). 2008; 73(11):1200-6.

23. Tong A, Gou L, Lau QC, Chen B, Zhao X, Li J, Tang H, Chen L, Tang M, Huang C*, Wei YQ*. Proteomic profiling identifies aberrant epigenetic modifications induced by hepatitis B virus X protein. J Proteome Res. 2009 Feb;8(2):1037-46.

22. Gao F, Huang C, Lin M, Wang Z, Shen J, Zhang H, Jiang L, Chen Q*. Frequent   inactivation of RUNX3 by promoter hypermethylation and protein mislocalization in oral squamous cell carcinomas. J Cancer Res Clin Oncol. 2009 May;135(5):739-47.

21. Li Z, Huang C, Bai S, Pan X, Zhou R, Wei Y*, Zhao X. Prognostic evaluation of epidermal fatty acid-binding protein and calcyphosine, two proteins implicated in endometrial cancer using a proteomic approach. Int J Cancer. 2008 Nov 15;123(10):2377-83.

20. Liu R, Li Z, Bai S, Zhang H, Tang M, Lei Y, Chen L, Liang S, Zhao YL, Wei Y, Huang C*. Mechanism of cancer cell adaptation to metabolic stress: proteomics identification of a novel thyroid hormone-mediated gastric carcinogenic signaling pathway. Mol Cell Proteomics. 2009 Jan;8(1):70-85.

19. Liang S*, Xu Y, Shen G, Zhao X, Zhou J, Li X, Gong F, Ling B, Fang L, Huang C, Wei Y. Gene expression and methylation status of 14-3-3sigma in human renal carcinoma tissues. IUBMB Life. 2008 Aug;60(8):534-40.

18. Tong A, Wu L, Lin Q, Lau QC, Zhao X, Li J, Chen P, Chen L, Tang H, Huang C, Wei YQ*. Proteomic analysis of cellular protein alterations using a hepatitis B virus-producing cellular model. Proteomics. 2008 May;8(10):2012-23.

17. Wang Z, Jiang L, Huang C*, Li Z, Chen L, Gou L, Chen P, Tong A, Tang M, Gao F, Shen J, Zhang Y, Bai J, Zhou M, Miao D, Chen Q*. Comparative proteomics approach to screening of potential diagnostic and therapeutic targets for oral squamous cell carcinoma. Mol Cell Proteomics. 2008 Sep;7(9):1639-50.

16. Li Z, Liu Y, Zhao X*, Pan X, Yin R, Huang C, Chen L, Wei Y. Honokiol, a natural therapeutic candidate, induces apoptosis and inhibits angiogenesis of ovarian tumor cells. Eur J Obstet Gynecol Reprod Biol. 2008 Sep;140(1):95-102.

15. Li Z, Zhao X*, Bai S, Wang Z, Chen L, Wei Y, Huang C*. Proteomics identification of cyclophilin a as a potential prognostic factor and therapeutic target in endometrial carcinoma. Mol Cell Proteomics. 2008 Oct;7(10):1810-23.

14. Wang YS, Wang GQ, Wen YJ, Wang L, Chen XC, Chen P, Kan B, Li J, Huang C, Lu Y, Zhou Q, Xu N, Li D, Fan LY, Yi T, Wu HB, Wei YQ*. Immunity against tumor angiogenesis induced by a fusion vaccine with murine beta-defensin 2 and mFlk-1.   Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6779-87.

13. Tong A, Zhang H, Li Z, Gou L, Wang Z, Wei H, Tang M, Liang S, Chen L, Huang C*, Wei Y*. Proteomic analysis of liver cancer cells treated with suberonylanilide hydroxamic acid. Cancer Chemother Pharmacol. 2008 Apr;61(5):791-802.

12. Shen J, Huang C, Jiang L, Gao F, Wang Z, Zhang Y, Bai J, Zhou H, Chen Q*. Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines. Biochem Pharmacol. 2007 Jun15;73(12):1901-9.

11. Chao G, Fan L, Jia W, Qian Z*, Gu Y, Liu C, Ni X, Li J, Deng H, Gong C, Gou M, Lei K, Huang A, Huang C, Yang J, Kan B, Tu M. Synthesis, characterization and hydrolytic degradation of degradable poly(butylene terephthalate)/poly(ethyleneglycol) (PBT/PEG) copolymers. J Mater Sci Mater Med. 2007 Mar;18(3):449-55.

10. Huang C, Ida H, Ito K, Zhang H, Ito Y*. Contribution of reactivated RUNX3 to inhibition of gastric cancer cell growth following suberoylanilide hydroxamic acid (vorinostat) treatment. Biochem Pharmacol. 2007 Apr 1;73(7):990-1000.

9. Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, Inoue M, Putti TC, Loh M, Ko TK, Huang C, Bhalla KN, Zhu T, Ito Y*, Sukumar S*. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res. 2006 Jul 1;66(13):6512-20.

8. Ito K, Liu Q, Salto-Tellez M, Yano T, Tada K, Ida H, Huang C, Shah N, Inoue M, Rajnakova A, Hiong KC, Peh BK, Han HC, Ito T, Teh M, Yeoh KG, Ito Y*. RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res. 2005 Sep 1;65(17):7743-50. Erratum in: Cancer Res. 2006 Mar 15;66(6):3345.


7. Zhang X, Huang C, Tang X, Zhuang Y, Hew CL*. Identification of structural proteins from shrimp white spot syndrome virus (WSSV) by 2DE-MS. Proteins. 2004 May 1;55(2):229-35.

6. Huang C, Zhang X, Gin KY, Qin QW*. In situ hybridization of a marine fish virus, Singapore grouper iridovirus with a nucleic acid probe of major capsid protein. J Virol Methods. 2004 May;117(2):123-8.

5. Zhang X, Huang C, Qin Q*. Antiviral properties of hemocyanin isolated from shrimp Penaeus monodon. Antiviral Res. 2004 Feb;61(2):93-9.

4. Huang C, Zhang X, Lin Q, Xu X, Hew CL*. Characterization of a novel envelope protein (VP281) of shrimp white spot syndrome virus by mass spectrometry. J Gen Virol. 2002 Oct;83(Pt 10):2385-92.

3. Huang C, Zhang X, Lin Q, Xu X, Hu Z, Hew CL*. Proteomic analysis of shrimp white spot syndrome viral proteins and characterization of a novel envelope protein VP466. Mol Cell Proteomics. 2002 Mar;1(3):223-31.

2. Zhang X, Huang C, Xu X, Hew CL*. Identification and localization of a prawn white spot syndrome virus gene that encodes an envelope protein. J Gen Virol. 2002 May;83(Pt 5):1069-74.

1. Zhang X, Huang C, Xu X, Hew CL*. Transcription and identification of an envelope protein gene (p22) from shrimp white spot syndrome virus. J Gen Virol. 2002 Feb;83(Pt 2):471-7.